Leap Therapeutics
47 Thorndike St, Suite B1-1
Cambridge
Massachusetts
02141
United States
Website: http://www.leaptx.com/
137 articles about Leap Therapeutics
-
Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference
1/11/2023
Leap Therapeutics, Inc. today announced that Douglas E. Onsi , President and Chief Executive Officer, Cynthia Sirard, MD, Chief Medical Officer, and Jason Baum, PhD., Vice President and Head of Translational Medicine will present a corporate overview at B. Riley Securities' 3rd Annual Oncology Conference.
-
Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference
11/21/2022
Leap Therapeutics, Inc. today announced that Douglas E. Onsi , President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held in New York.
-
Leap Therapeutics Reports Third Quarter 2022 Financial Results
11/14/2022
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2022.
-
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
10/17/2022
Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 antibody.
-
Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer
10/12/2022
Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced that the first patient has been enrolled in the randomized controlled Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm, in patients with gastric or gastroesophageal junction cancer (G/GEJ).
-
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
10/5/2022
Leap Therapeutics, Inc. today announced the Company will be presenting updated data from Part B of the DisTinGuish Study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody.
-
Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference
9/7/2022
Leap Therapeutics, Inc. announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference, being held in New York on September 13-14, 2022.
-
Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors
9/6/2022
Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022.
-
Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress
9/4/2022
Leap Therapeutics, Inc. announced the Company will be presenting data in first-line patients with advanced gastroesophageal adenocarcinoma from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy, at the European Society for Medical Oncology Congress 2022 being held on September 9-12.
-
Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute
8/12/2022
Leap Therapeutics, Inc. today announced that its Board member, Monica Bertagnolli , MD, has been appointed as the 16th Director of the National Cancer Institute.
-
Leap Therapeutics Reports Second Quarter 2022 Financial Results
8/12/2022
Leap Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2022.
-
Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer
7/12/2022
Leap Therapeutics, Inc. (NASDAQ: LPTX), and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), today announced the initiation of Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap's anti-SSEDickkopf 1 (DKK1) antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody.
-
Leap Therapeutics to Host Virtual R&D Day on July 12, 2022
6/27/2022
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a virtual R&D Day on July 12, 2022 at 12:00 pm ET.
-
Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting
5/26/2022
Leap Therapeutics, Inc. (Nasdaq: LPTX), today announced that initial clinical data from the investigator-sponsored Phase 1b/2a dose escalation and dose expansion study testing Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, as monotherapy or in combination with docetaxel in metastatic castration-resistant prostate cancer (mCRPC) will be presented at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Leap Therapeutics Reports First Quarter 2022 Financial Results
5/13/2022
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2022.
-
Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
3/11/2022
Leap Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2021.
-
Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference
3/2/2022
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer will present a corporate overview at Raymond James Institutional Investors Conference.
-
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
-
Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference
1/24/2022
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, and Cynthia Sirard, MD, Chief Medical Officer, will present a corporate overview at the B. Riley Securities Oncology Investor Conference.
-
Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium
1/18/2022
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody.